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C-type lectin receptors (CLRs) are carbohydrate-binding receptors that recognize 
their ligands often in a Ca2+-dependent manner. Upon ligand binding, myeloid CLRs 
in innate immunity trigger or inhibit a variety of signaling pathways, thus initiating or 
modulating effector functions such as cytokine production, phagocytosis, and antigen 
presentation. CLRs bind to various pathogens, including viruses, fungi, parasites, and 
bacteria. The bacterium Campylobacter jejuni (C. jejuni) is a very frequent Gram-negative 
zoonotic pathogen of humans, causing severe intestinal symptoms. Interestingly, 
C. jejuni expresses several glycosylated surface structures, for example, the capsular 
polysaccharide (CPS), lipooligosaccharide (LOS), and envelope proteins. This “Methods” 
paper describes applications of CLR–Fc fusion proteins to screen for yet unknown 
CLR/bacteria interactions using C. jejuni as an example. ELISA-based detection of 
CLR/bacteria interactions allows a first prescreening that is further confirmed by flow 
cytometry-based binding analysis and visualized using confocal microscopy. By 
applying these methods, we identified Dectin-1 as a novel CLR recognizing two selected 
C. jejuni isolates with different LOS and CPS genotypes. In conclusion, the here- 
described applications of CLR–Fc fusion proteins represent useful methods to screen for 
and identify novel CLR/bacteria interactions.
Keywords: C-type lectin receptors, Campylobacter jejuni, innate immunity, flow cytometry, confocal microscopy, 
eLIsA assay, screening tools, dectin-1 receptor
INtRodUCtIoN
C-type lectin receptors (CLRs) are pattern recognition receptors and are known to sense pathogen-
associated molecular patterns as well as danger-associated molecules. Upon ligand recognition, CLRs 
trigger a variety of functions, including the production of inflammatory mediators, the phagocytosis 
of pathogens, or intracellular signaling (1, 2). The carbohydrate recognition domain (CRD) mediates 
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the binding of CLRs to their specific ligands. One well-described 
example for a CLR–ligand pair is the CLR Mincle and its ligand 
trehalose-6,6'-dimycolate (TDM), a unique glycolipid present in 
the cell wall of mycobacteria (3, 4). Crystal structure analyses of 
the bovine (5) and human (6) Mincle CRD revealed that the two 
glucose moieties and one acyl chain of TDM and its synthetic 
analog trehalose-6,6'-dibehenate interact with Mincle. However, 
for the majority of CLRs, their glycan ligands and binding mode 
to their respective ligands are still incompletely understood.
The main function of CLRs is the recognition of highly 
conserved glycans and glycoproteins located on the surface of path-
ogens including viruses, parasites, fungi, and bacteria (3, 7–9). 
However, CLRs may also sense endogenous danger signals 
released by damaged and necrotic cells (10–13). Dectin-1 is a CLR 
that is predominantly expressed by monocytes, dendritic cells 
(DCs), and macrophages (14). It has been described to bind to 
β-1,3-glucans present in the cell wall of several fungal pathogens. 
Dectin-1 was shown to recognize various fungal pathogens such 
as Pneumocystis carinii, Candida albicans, Aspergillus fumigatus, 
and Cryptococcus neoformans (15).
Fc fusion proteins are established tools to identify novel recep-
tor–ligand interactions. To date, CLR–Fc fusion proteins have 
been successfully used to screen for novel CLR/pathogen interac-
tions, as demonstrated for fungal interactions, such as the recog-
nition of P. carinii by Mincle (16). In addition, several previously 
unknown CLR/bacteria interactions were identified using CLR–Fc 
fusion proteins, including the Mincle/Streptococcus pneumoniae 
(S. pneumoniae) interaction (17) or the SIGNR3/Lactobacillus 
acidophilus interaction (18). Moreover, CLEC5A (MDL-1) was 
found to be an important receptor for Listeria monocytogenes 
that impacts macrophage and neutrophil functions in Listeria-
induced innate immunity (19). Recently, CLR–Fc fusion proteins 
were used to identify novel CLRs that interact with mycobacteria. 
Here, CLEC9A was identified as a receptor that was crucial for the 
regulation of signal transduction and cytokine production during 
Mycobacterium tuberculosis infection (20). Besides the identifica-
tion of pathogen-derived CLR ligands, CLR–Fc fusion proteins 
also allow to screen carbohydrate libraries for novel CLR ligands. 
Identified ligands can then be further evaluated for their utility 
to target CLRs on antigen-presenting cells (21–24). Indeed, the 
ligation of cell surface CLRs can induce various responses such 
as phagocytosis, cell adhesion, cytokine and chemokine release, 
as well as antigen presentation (25), rendering CLRs promising 
targets for immune modulation.
The enteropathogen Campylobacter jejuni (C. jejuni) expresses 
various virulence factors that allow for motility, adhesion, and 
invasion of host tissue, leading not only to acute self-limiting 
gastrointestinal illness but also to autoimmune disorders like 
Guillain–Barré syndrome (26, 27). Diarrheal Campylobacter 
species can colonize the intestines of many different host species, 
ranging from farm animals such as cattle and chicken to humans. 
Interestingly, they persistently colonize most nonhuman spe-
cies without overt symptoms, verging on commensalism, while 
they cause acute intestinal disease in humans (28). C. jejuni is 
genetically quite variable and exists as generalist variants able to 
colonize various host species equally well (29, 30) and as special-
ist variants, which usually have only one preferred host species 
(31). In addition, each individual C. jejuni strain has the intrinsic 
property to vary its phenotype, for instance, by phase variation 
and contingency genes (32, 33). Campylobacter sp. are the only 
bacteria to date which express functional N- and O-glycosylation 
modules (34). Surface-exposed glycolipids such as the capsular 
polysaccharide (CPS) (35) and the lipooligosaccharide (LOS) (36) 
of the outer membrane play a pivotal role in host interaction and 
evasion by C. jejuni. In addition, C. jejuni expresses several cell-
envelope-located O- and N-linked glycoproteins (37, 38). Recent 
studies identified CLRs that are involved in C. jejuni recognition 
(39, 40). In one study, hMGL–Fc was shown to interact with 
C. jejuni-derived glycoproteins (39). Another study used a murine 
CLR–hFc fusion protein library and showed LMIR5 to bind to 
C. jejuni (40). These studies point to a role of CLRs in host inter-
play and modulating the host immune response against C. jejuni.
This “Methods” paper presents a combination of innovative 
techniques to screen for and study CLR/bacteria interactions, 
using C. jejuni as a representative example. All applied methods 
are based on CLR–hFc fusion proteins in which the extracellular 
part of the respective murine (m) or human (h)CLR containing the 
CRD has been fused to the Fc fragment of human IgG1 molecules, 
thus leading to dimer formation. ELISA-based methods allow for 
a high-throughput prescreening for potential CLR interactions 
with bacteria, followed by flow-cytometric analyses of identified 
candidates as a confirmatory method. To visualize and confirm 
binding of CLRs to bacteria in situ, confocal microscopy can be 
applied and was used in this study to visualize the binding of 
Dectin-1 to C. jejuni.
MAteRIALs ANd Methods
C. jejuni strains, Culture Conditions, and 
Preparation of Bacteria for Interaction 
studies
Campylobacter jejuni strains used were from two strain collec-
tions (29, 41) assembled in Germany between 2011 and 2016. We 
selected two different, but related, generalist strains that are from 
two frequent C. jejuni lineages that can colonize well with various 
animal species including humans and that cause frequent diar-
rheal diseases in the latter. Strain MHH-24 is equivalent to isolate 
FBI-Zoo 06025 (ST22) from Ref. (29) and was isolated from raw 
milk (cattle), and strain MHH-19, a human enteritis isolate, is 
equivalent to isolate FBI-Zoo 07079 (ST19) from the more recent 
case–control study (41). MHH-19 has well-recognized genetic 
determinants for capsule and LOS types (own unpublished 
data); however, strain MHH-24 has not been typeable so far by 
molecular methods for LOS or CPS (own unpublished data). 
Both strains’ LOS and CPS glycans or other surface glycans have 
not been characterized biochemically so far. For the plate assay 
and FACS-based assay, heat-fixed bacteria were used, which allow 
for better staining of the bacteria with the fluorescent Syto61 dye 
(Thermo Scientific), while for immunofluorescent individual 
bacterial labeling, PFA-fixed bacteria were prepared, which per-
mit a superior surface preservation of the cells and better storage 
capacity. Bacteria were grown on blood agar plates (Columbia 
agar, supplemented with 5% sheep blood, Oxoid, Germany) 
tABLe 1 | DNA sequences of primers used for amplification of the extracellular 
domain of the respective CLRs.
CLR Primer
mCLEC12A FW 5'- GAATTCTTTGGCAACAGAAATGATAA-3'
RV 5'- AGATCTGCCATTCAACACACTTTCCA-3'
mDectin-1 FW 5'- GAATTCTTCAGGGAGAAATCCAGAGG-3'
RV 5'- AGATCTTGAAGAAGTATTGCAGATTTGGTT-3'
mDectin-2 FW 5'- CCATGGAGAAAACATCATTCCAGCCCC-3'
FW 5'- GAATTCCTGGAGCACCAGTGAGCAGAAC-3'
mCLEC9a FW 5'-GAATTCGGGCATCAAGTTCTTCCAGGTATCC-3'
RV 5'-CCATGGTGCAGGATCCAAATGCCTTCTTC-3'
mDCAR FW 5'- CCATGGAACTTGACAGGTACCATTCATT-3'
RV 5'- AGATCTTAAGTTTATTTTCTTCATCTGAC-3'
mSIGNR3 FW 5'- GAATTCCATGCAACTGAAGGCTGAAG-3'
RV 5'- AGATCTTTTGGTGGTGCATGATGAGG-3'
mMGL-1 FW 5'- CCAGTTAAGGAGGGACCTAGGCAC-3'
RV 5'- AGCTCTCCTTGGCCAGCTTCATC-3'
mMDL-1 FW 5'- GAATTCCCCCACGGAGAGCTACGGAACCA-3'
RV 5'- CCATGGTGGCATTCATTTCGCAGATCCA-3'
hDC-SIGN FW 5'- GAATTCCATGCAACTGAAGGCTGAAG-3'
RV 5'- GATCTTTTGGTGGTGCATGATGAGG-3'
hL-SIGN FW 5'- GAATTCCTATCAAGAACTGACCGATTTG-3'
RV 5'- CCATGGATTCGTCTCTGAAGCAGGC-3'
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and diluted in sterile 1x PBS at an OD600 of 1. Heat fixation was 
performed at 65°C in a heating block for 5 h. Heat-inactivated 
bacteria were stored at 4°C for a maximum of 3 weeks. Fresh 2% 
PFA as an alternative fixing agent for immunofluorescent labeling 
was prepared in 100  mM sterile-filtered potassium phosphate 
buffer, pH = 7.0, and bacteria were fixed twice for 1 h at room 
temperature (RT), with centrifugation (6.000 × g, 10 min, RT) 
and one change of fixing agent in between. Afterward, the bacte-
ria were centrifuged again and resuspended in a sterile solution 
of 0.1% glycine in PBS to quench the fixing agent, which prevents 
nonspecific attachment of proteins or cell clumping. Ultimately, 
the bacteria were resuspended in pure, sterile 1× PBS (pH = 7.4) 
after a final centrifugation step and stored at 4°C until further use, 
with a high storage capacity of several months.
Generation of CLR–hFc Fusion Proteins
The production of the CLR–hFc fusion proteins was performed 
as previously described (23). Briefly, RNA was isolated from 
murine spleen and reverse-transcribed into cDNA using a 
reverse transcriptase (New England Biolabs, Ipswich, MA, 
USA). Polymerase chain reaction was applied to amplify the 
cDNA encoding the extracellular part of each CLR using specific 
primers (Table 1). The respective cDNA fragments were ligated 
into a pFuse-hIgG1-Fc expression vector (InvivoGen, San Diego, 
CA, USA). Next, CHO-S cells were transiently transfected with 
the vector construct using MAX reagent (InvivoGen). CLR–hFc 
fusion proteins were purified after 4  days of transfection from 
the cell supernatant using HiTrap protein G HP columns (GE 
Healthcare, Piscataway, NJ, USA). To confirm the purity of each 
CLR–hFc fusion protein, the protein was analyzed by dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and 
subsequent Coomassie staining as well as Western blot using 
an anti-human IgG- horseradish peroxidase (HRP) antibody 
(Dianova, Hamburg, Germany).
Western Blot
After protein separation using SDS-PAGE, the proteins were 
transferred to a nitrocellulose membrane for 1  h at 5  V. The 
membrane was blocked for 1 h with 5% milk powder in TBS and 
0.1% Tween-20 (TBS-T) followed by a 1-h incubation with an 
anti-human IgG antibody conjugated to HRP (Dianova). The 
membrane was washed three times with TBS-T, for 5 min each. 
Detection of the CLR–hFc fusion proteins was performed using 
the Amersham ECL Western blotting detection reagent (GE 
Healthcare).
eLIsA-Based Binding studies
A half-area microplate (Greiner Bio-One GmbH, Frickenhausen, 
Germany) was coated with 3 ×  108  CFU/ml heat-inactivated 
C. jejuni for 3.5 h at RT. Non-adherent bacteria were washed 
away, and the plate was blocked with buffer containing 1% BSA 
(Thermo Fisher Scientific/Invitrogen, Darmstadt, Germany) 
in 1x PBS for 2  h at RT. After washing the wells, 200  ng of 
each respective CLR–hFc fusion protein in lectin-binding 
buffer (50  mM HEPES, 5  mM MgCl2, and 5  mM CaCl2) was 
added to the bacteria and incubated for 1  h at RT. Then, a 
1:5.000-diluted HRP-conjugated goat anti-human IgG anti-
body (Dianova) was added for 1 h at RT. Finally, the substrate 
solution [o-phenylenediamine dihydrochloride substrate tablet 
(Thermo Fisher Scientific), 24 mM citrate buffer, 0.04% H2O2, 
50  mM phosphate buffer in H2O] was added to the samples, 
and the reaction was stopped with 2.0  M sulfuric acid. Data 
was collected using a Multiskan Go microplate spectropho-
tometer (Thermo Fisher Scientific) at a wavelength of 495 nm. 
Four independent experiments were performed with technical 
triplicates each.
Flow Cytometry-Based Binding studies
To detect the bacteria and exclude them from debris, 
3–6 ×  107 CFU/ml heat-inactivated C. jejuni were stained with 
1 µM of the DNA-staining dye Syto61 (Thermo Fisher Scientific) 
and incubated for 30 min at RT. Subsequently, samples were incu-
bated for 1 h with 200 ng of the respective CLR–hFc fusion protein 
in lectin-binding buffer. After washing once with lectin-binding 
buffer, the bacterial pellet was stained with a PE-conjugated goat 
anti-human Fc (Dianova) antibody solution and incubated for 
25 min at 4°C. Finally, flow-cytometric analysis was performed 
using an Attune NxT Flow Cytometer (Thermo Fisher Scientific). 
Data analysis was performed using the FlowJo Software (FlowJo, 
Ashland, OR, USA). As a control, hFc protein was used to exclude 
the nonspecific binding of C. jejuni to the Fc part of the CLR–Fc 
fusion proteins. Besides the use of the hFc protein, the secondary 
antibody alone served as an additional negative control. Three 
independent experiments were done with technical duplicates 
each.
Confocal Fluorescence Microscopy-Based 
Binding studies
Cover slides (Thermo Fisher Scientific) were cleaned with 70% 
ethanol and coated with poly-L-lysine solution (Sigma-Aldrich, 
St. Louis, MO, USA) for 30 min at 60°C. 6 × 107 CFU/ml C. jejuni 
FIGURe 1 | (A) Overview of the generation and production of C-type lectin receptor (CLR)–hFc fusion proteins. (1) First, the cDNA encoding for the carbohydrate 
recognition domain of the respective CLR is cloned into the expression vector and thereby fused to the cDNA fragment encoding for human IgG1-Fc. (2) CHO-S 
cells are transiently transfected with the expression vector construct, and the respective soluble CLR–hFc fusion proteins are secreted. (3) The cell supernatant is 
purified, and (4) the presence of the CLR–Fc fusion proteins is detected. (B) Western blot of selected CLR–hFc fusion proteins. To confirm the successful CLR–hFc 
fusion protein production, supernatants of transiently transfected cells were purified using protein G columns, and detection by Western blot was performed using a 
horseradish peroxidase-conjugated anti-hFc antibody.
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isolate MHH-19 fixed with 2% PFA was washed with 1x PBS and 
incubated overnight (o.n.) with 500 ng Dectin-1–hFc and hFc in 
lectin-binding buffer at 4°C. After washing two times with lectin-
binding buffer, samples were incubated for 2 h with 1:200-diluted 
goat anti-human Fc Alexa Fluor (AF) 488-conjugated antibody 
(Dianova) at 4°C. Next, samples were washed with 1x PBS, applied 
onto poly-L-lysine-coated cover slides, and incubated for 45 min 
at 37°C. In addition, a sample with C. jejuni and the secondary 
antibody only was used as a negative control. Finally, the cover 
slides were mounted on microscopic slides (Roth, Karlsruhe, 
Germany) with proLong™ gold antifade mountant containing 
DAPI (Thermo Fisher Scientific), sealed and visualized using a 
TCS SP5 confocal inverted-base fluorescence microscope (Leica, 
Nussloch, Germany) equipped with a HCX PL APO 63 ×  1.4 
oil immersion objective. To avoid the detection of artifacts, 
PFA-fixed bacterial samples were inspected visually by a high-
magnification microscopy (100× lens magnification) for clumps 
before performing hFc fusion protein co-incubation. Only bacte-
rial preparations without any visible clumps were further used. 
Three independent experiments were performed, each with three 
randomly selected pictures.
statistical Analysis
All data are presented as mean  ±  SD. Unpaired, one-tailed 
Student’s t-test was applied to determine the significance between 
CLR candidates and the hFc control. Data were analyzed using 
the GraphPad Prism software (version 7.02).
ResULts
Generation and detection of CLR–hFc 
Fusion Proteins Used in this study
The generation of CLR–hFc fusion proteins required several steps 
(Figure 1A, 1–4). The first step was the cloning of the cDNA frag-
ment encoding for the extracellular part of each CLR (containing 
the CRD) and its fusion to the Fc fragment of human IgG1 in the 
pFuse-hIgG1-Fc expression vector (1). Next, mammalian CHO-S 
cells were transfected with this vector construct (2). The use of a 
mammalian cell line such as CHO-S cells ensured that soluble 
CLR–hFc fusion proteins were secreted into the supernatant that 
carried mammalian-type glycosylation. Finally, the supernatant 
was harvested, followed by purification of the respective fusion 
FIGURe 2 | (A) Schematic representation of the ELISA-based-binding study using the C-type lectin receptor (CLR)–hFc fusion proteins. Immobilized C. jejuni was 
incubated with the respective CLR–hFc fusion proteins. The detection of bound fusion proteins was performed using a horseradish peroxidase (HRP)-conjugated 
anti-hFc antibody and subsequent colorimetric detection (details are given in Section “Materials and Methods”). (B) Several CLR–hFc fusion proteins were analyzed 
for their interaction with heat-inactivated immobilized C. jejuni. This prescreening showed no or only marginal binding of DCAR–hFc and L-SIGN–hFc. The CLR–hFc 
fusion proteins CLEC9A, DC-SIGN, Dectin-1, Dectin-2, MDL-1, MGL-1, CLEC12A, and SIGNR3 exhibited weak to marked binding to both C. jejuni isolates. 
Representative data from one out of four independent experiments are shown (technical triplicates for each condition). The dashed line represents the defined 
threshold for CLR/bacteria interactions in the ELISA-based assay. Student’s t-test was performed to compare all CLR–hFc fusion proteins with absorbance above 
the threshold to the hFc control alone. For both C. jejuni isolates, a highly significant binding (****p ≤ 0.0001) was observed for the CLR–hFc fusion proteins 
mCLEC12A–hFc, mDectin-1–hFc, mDectin-2–hFc, mCLEC9A–hFC, mSIGNR3–hFC, mMGL-1–hFc, mMDL-1–hFc, and hDC-SIGN–hFc.
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proteins using protein G columns (3). To confirm the presence 
and purity of the respective CLR–hFc fusion proteins after puri-
fication, SDS-PAGE and subsequent Coomassie staining and a 
Western blot were performed (Figure 1B). Bands at the expected 
size of the respective CLR–hFc fusion protein showed the pres-
ence of each CLR–hFc fusion protein.
Prescreening Using an eLIsA-Based 
Assay
In a first screening, the binding of the CLR–hFc fusion proteins 
to two different C. jejuni isolates (MHH-19 and MHH-24) was 
tested using an ELISA-based method. After immobilization of 
the heat-inactivated bacteria on the ELISA plate and incubation 
with the respective CLR–hFc fusion proteins, their interac-
tion with the C. jejuni isolates was determined by colorimetric 
detection (Figure  2A). Several controls were included, such as 
the incubation of the CLR–hFc fusion proteins on non-coated 
wells (data not shown) or with the hFc protein alone to exclude 
unspecific binding of the Fc fragment to C. jejuni. In general, the 
CLR–hFc fusion proteins exhibited a similar binding pattern to 
both C. jejuni isolates (Figure 2B). No binding was observed for 
DCAR–hFc and L-SIGN–hFc. All other CLR–hFc fusion proteins 
displayed weak to strong binding to C. jejuni in the ELISA-based 
assay and were considered as potential receptors for the C. jejuni 
isolates MHH-19 and MHH-24.
Confirmatory test Using a Flow 
Cytometry-Based Assay
To verify and extend the results from the ELISA-based detection 
method, a flow cytometry-based protocol to screen for CLR/
bacteria interactions in solution was established. To this end, C. 
jejuni was incubated with CLR–hFc fusion proteins, and subse-
quent binding was detected upon staining with a PE-conjugated 
anti-hFc antibody (Figure 3A). The gating strategy is displayed in 
Figure 3B and is based on the gating of bacteria in the forward-
scatter/side-scatter plot, followed by gating on Syto61-positive 
events. Incubation with the Dectin-1–hFc fusion protein led 
to a marked shift in the fluorescence intensity, indicating the 
binding of Dectin-1–hFc to C. jejuni. For both C. jejuni isolates, 
no binding was observed for staining with the hFc fragment or 
with the secondary antibody alone. The lack of binding of the 
hFc fragment to C. jejuni illustrates the specificity of the rec-
ognition of the C. jejuni isolates by Dectin-1–hFc. The analysis 
of the binding studies shows that both tested C. jejuni isolates 
were significantly recognized by Dectin-1–hFc and, to a lesser 
extent, by CLEC12A–hFc (Figure 3C). All other CLR–hFc fusion 
FIGURe 3 | (A) Overview of the flow cytometry-based protocol to detect bacterial recognition by C-type lectin receptor (CLR)–hFc fusion proteins. C. jejuni was 
incubated with the respective CLR–hFc fusion proteins in solution. Binding was detected using an anti-hFc antibody. Subsequently, samples were analyzed by flow 
cytometry based on their morphological and fluorescence properties. (B) Histoplots show the gating strategy to detect the binding of CLR–hFc fusion proteins to C. 
jejuni in a representative experiment. Cells were discriminated from debris by gating on forward scatter (FSC) and side scatter (SSC). C. jejuni was further gated on 
DNA staining, indicated by Syto61 positivity (pos.). Finally, Syto61-positive bacteria were analyzed for Dectin-1–hFc binding. hFc and  
the secondary antibody alone were used as controls. (C) Representative data from one out of three independent experiments of the flow cytometry-based  
CLR–hFc-binding studies to the C. jejuni isolates MHH-19 and MHH-24 (technical duplicates each). Similar binding profiles for both isolates were observed. While 
Dectin-1–hFc and CLEC12A–hFc exhibited binding to C. jejuni, all other tested CLR–Fc fusion proteins displayed marginal to no binding. The dashed line represents 
the defined threshold for CLR/bacteria interactions in the flow cytometry-based assay. Data are expressed as mean ± SD. Student’s t-test was performed to 
compare the binding of CLR–Fc fusion proteins above the threshold to hFc alone. For all statistical analyses, p-values of <0.05 were considered to be significant: 
ns = not significant, *p ≤ 0.05, **p ≤ 0.01.
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proteins included in the flow cytometry-based assay exhibited no 
or only marginal binding to both C. jejuni isolates. Interestingly, 
no binding of CLEC9A–hFc to both C. jejuni isolates was detected 
using the flow cytometry-based assay. This finding may either 
suggest a false-positive result in the ELISA-based assay or may be 
due to internal C. jejuni ligands that are not accessible in the flow 
cytometry-based assay. In summary, the CLR–hFc fusion proteins 
exhibited a similar binding profile to both C. jejuni isolates in the 
FIGURe 4 | (A) Schematic representation of the C-type lectin receptor (CLR)–hFc fusion protein-binding studies using confocal microscopy. Bacteria were 
incubated with the CLR–hFc fusion proteins. Bound CLR–hFc fusion proteins were detected by an Alexa Fluor (AF) 488-conjugated anti-hFc antibody. To exclude 
unspecific binding, bacteria were also incubated with hFc as control protein or with the secondary antibody alone. Bacteria were transferred onto cover slips, 
mounted onto microscopic slides, and visualized using confocal microscopy. (B) Bacteria were incubated with Dectin-1–hFc (upper panels) or hFc protein (negative 
control, lower panels). Differential interference contrast (DIC) was included to visualize the bacterial cell wall. Bacterial DNA was stained with DAPI (shown in blue). 
The binding of the Dectin-1–Fc fusion protein to C. jejuni was detected using an AF488-conjugated secondary antibody (shown in green). While Dectin-1–hFc 
recognizes C. jejuni, the hFc control and the secondary antibody alone showed no signal in the AF488 channel. The experiment was repeated three times with three 
randomly selected pictures each, and similar results were revealed. Scale bar indicates 2.5 µm.
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flow cytometry-based assays and revealed Dectin-1 as a novel 
candidate receptor for C. jejuni recognition.
Visualization of CLR/Bacteria Interactions 
Using Confocal Microscopy
To visualize the identified Dectin-1–hFc interaction with C. jejuni 
in  situ, confocal microscopy after immunofluorescent labeling 
was applied. The incubation of C. jejuni with Dectin-1–hFc and 
hFc control protein was performed in solution. Subsequently, 
bacteria were immobilized on poly-L-lysine-coated cover slides, 
and individual CLR/C. jejuni interactions were visualized using 
a confocal laser-scanning microscope (Figure  4A). The results 
confirmed Dectin-1 binding to C. jejuni, whereas no binding 
was observed for hFc (Figure 4B) and the secondary antibody 
alone (data not shown). Furthermore, merging the fluorescence 
tABLe 2 | Advantages and drawbacks of the ELISA-based, flow cytometry-
based, and confocal microscopy-based methods to detect novel CLR/bacteria 
interactions.
Method Advantages drawbacks Main 
purpose
ELISA - High-throughput screening 
possible
- Fast screening
- False-positive 
results possible 
due to protein 
aggregation on the 
plate
- Requires pure 
pathogen samples
Prescreening 
for CLR/
bacteria 
interactions
Flow 
cytometry
- Semi-quantitative 
comparisons possible
- Exclusion of debris due to 
appropriate gating
- Information on a large 
number of cells for 
statistical analyses
- Restricted to 
detectable events 
in SSC and FSC
- Limited to 
ligands present 
on the surface 
of pathogens 
(can also be an 
advantage)
Confirmation 
of CLR/
bacteria 
interactions
Microscopy - Colocalization studies 
possible
- Visualization of CLR 
interactions with single 
bacteria (detection of intra-
strain variation)
- Extracellular and 
intracellular staining 
possible (preserved 
structure)
- Time-consuming
- Requires 
advanced staining 
protocols
Direct 
visualization 
of CLR/
bacteria 
interactions
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channels and the differential interference contrast showed that 
the Dectin-1–hFc signal colocalized with patches on the bacterial 
cell periphery. This finding suggests that Dectin-1–hFc recognizes 
a cell-envelope component of C. jejuni. In conclusion, the com-
bination of ELISA-, flow cytometry-, and confocal microscopy-
based methods highlights the utility of CLR–Fc fusion proteins 
to identify novel CLR/bacteria interactions as demonstrated here 
using C. jejuni as an example. The functional role of the C. jejuni 
recognition by Dectin-1 can now be further elucidated in future 
studies.
dIsCUssIoN
This article presents three distinct methods to detect and verify 
novel CLR/bacteria interactions. Often, the identification of 
novel CLR/pathogen interactions is the first step to unravel the 
interplay of the host innate immune system with bacterial patho-
gens. Each of the methods can be applied for different purposes 
and has certain advantages and drawbacks (presented in Table 2). 
The ELISA-based method allows for a high-throughput screen-
ing of bacteria collections. Due to the possibility of false-positive 
results caused by protein aggregation on the ELISA plate, this 
method is mainly suitable for an initial prescreening using the 
whole CLR–hFc fusion protein library and requires confirma-
tion by additional methods. To confirm initially identified CLR/
bacteria interactions, flow-cytometric analysis represents a useful 
method that has several advantages. First, binding takes place in 
solution, thus avoiding protein aggregation on the ELISA plate. 
Second, the flow cytometry-based method offers the possibility 
to discriminate between bacteria and debris using an appropriate 
gating strategy. Third, it allows for narrowing down the localiza-
tion of ligands to the bacterial surface, whereas the ELISA-based 
method may lead to a partial lysis of bacteria, thus releasing 
internal ligands. By contrast, confocal (fluorescence) microscopy 
offers the opportunity of visualizing CLR/bacteria interactions 
for single-bacteria in situ, thus enabling colocalization studies to 
further characterize the bacterial ligand. All described methods 
can be easily applied to other Gram-positive and Gram-negative 
bacterial species.
Campylobacter jejuni is an interesting candidate for screening 
glycan-binding factors, since the bacteria are heavily glycosylated 
with various different glycan species and possess active genes for 
variable O- and N-glycosylation, providing abilities to glycosylate 
capsule, LOS, and proteins (34). In addition, strain-specific differ-
ences between various C. jejuni strains exist concerning surface 
determinants and glycosylation (42), based, for instance, on 
strain-specific genetic differences and phase variation (32). Even 
in each individual C. jejuni strain, a high-variation potential of 
the bacterial surface phenotype, for instance, LOS, capsule, or 
additional LOS glycosylation, exists (33, 43–45), which provides 
an interesting field of future study. Applying the CLR–hFc fusion 
protein library to screen for binding to preselected, molecularly 
typed C. jejuni isolates from two frequent generalist lineages, 
we identified Dectin-1–hFc as a promising candidate receptor 
for C. jejuni. Phongsisay et  al. screened C. jejuni lysates using 
a murine CLR–hFc fusion protein library (40). In this previous 
study, the murine CLR LMIR5 was described to interact with 
C. jejuni, whereas other tested CLR/C. jejuni interactions remained 
negative. In bacterial lysates, components such as glycolipids are 
released and better accessible to potential receptors as in intact 
live or heat-inactivated bacteria. Thus, the CLR/C. jejuni interac-
tions identified in the respective study may also include internal 
ligands that are not detected when intact bacteria are immobilized 
on the plate for ELISA-based detection or used in solution for 
the flow cytometry-based assay. In addition, the use of different 
C. jejuni strains or growth under different culture conditions may 
impact the recognition by CLRs. Since the surface interaction of the 
bacteria with host lectins might be more relevant for the coloniza-
tion and infection process in vivo, we employed heat-inactivated 
intact bacterial cells instead of bacterial lysates for our screening 
procedures. In our present study, both isolates used in our study, 
which are genetically related, but not identical, exhibited a similar 
CLR-binding profile. It will be interesting to compare more C. 
jejuni strains including distantly related isolates, generalists, and 
specialists (30, 31) for lectin binding. In addition, phase varia-
tion, which is a common genetic mechanism used by C. jejuni 
to modulate its surface properties (32), may play a role in CLR 
recognition. Indeed, phase variation between strains and within 
the population of one C. jejuni isolate (33) may affect cell wall 
components, as has already been shown for the glycosylation of 
LOS (43), capsule (44, 45), and for other bacterial properties (32). 
In this context, it is worth noting that in our confocal microscopy 
in  situ approach, bacterial cells showed an individual variation 
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in Dectin-1 binding or the absence of binding. Phenotypical 
variation of this trait within the bacterial population has not been 
revealed in any earlier study on C. jejuni and might be explained by 
single-cell variation of a Dectin-1-binding surface determinant. 
This presents a very interesting opportunity for further study of 
individual bacterial intra-strain variation. In an earlier study, 
human MGL was shown to recognize C. jejuni through binding to 
C. jejuni-derived N-glycosylated proteins (39). For murine MGL-
1, we observed only weak binding to C. jejuni, which may be due 
to experimental or strain differences, or to the different binding 
profiles between murine and human MGL isoforms. While two 
different orthologs (mMGL-1 and mMGL-2) are found in mice, 
humans only express one MGL isoform (hMGL). It is known 
that mMGL-2 displays a similar binding profile as hMGL which 
may account for the marginal binding observed for the mMGL-1 
ortholog in our study (46, 47).
In this study, we have identified mouse Dectin-1 as a candidate 
receptor for the innate recognition of C. jejuni. To date, Dectin-1 
has mainly been described as CLR-recognizing fungal pathogens. 
For instance, Dectin-1 binds to C. albicans, A. fumigatus, and 
C. neoformans (15). The Dectin-1 ligand recognized in the context 
of fungal infection is β-1,3-glucan (48), present in the cell wall 
of several fungi. Nevertheless, also parasites such as Leishmania 
infantum (49, 50) and P. carinii (51) were described to be sensed 
by Dectin-1. Interestingly, also an interaction of Dectin-1 in 
cooperation with TLR2 was shown for several Mycobacterium 
species (52). In C. jejuni, α-1,4-glucan has been reported as a 
capsule component (53).
The identification of candidate CLRs that play a role in bac terial 
recognition presents the first step to identify a distinct bacterial 
ligand for the respective receptor and may help to understand 
the interaction of bacteria with the host innate immune system. 
Identified CLR candidates can be further investigated for their 
relevance in vitro and in vivo. Using a comprehensive CLR–hFc 
library, Rabes et  al. demonstrated that Mincle recognizes 
S. pneumoniae in a Ca2+-dependent manner (17). This work 
was extended by a recent study showing that Mincle recognizes 
S. pneumoniae-derived glucosyl-diacylglycerol in a serotype-
specific fashion (54). To date, several CLR ligands have been 
identified by the use of CLR–Fc fusion proteins. For instance, 
one study revealed Mincle–hFc as a receptor sensing mannose 
and glucose-rich glycolipids extracted from Malassezia pachy­
dermatis (55). In addition, the identification of distinct glycan 
ligands of CLRs offers the possibility for glycan-based CLR 
targeting to deliver vaccine antigens into antigen-presenting 
cells and to induce subsequent adaptive immune responses (22, 
56–58). This approach has already been applied successfully 
to vaccine design using carbohydrate-based adjuvants (22, 
59, 60). Besides CLR–Fc fusion protein libraries, reporter cell 
lines expressing the respective CLR are used to identify novel 
CLR–pathogen interactions and CLR ligands (61, 62). In addi-
tion, such reporter cell lines also allow for investigating if the 
identified CLR ligands act as potential agonists or antagonists. 
In conclusion, this “Methods” paper combines three differ-
ent screening and confirmatory methods for the detection of 
CLR–hFc fusion protein binding by pathogens. It also highlights 
the utility of CLR–hFc fusion proteins to screen for novel CLR/
bacteria interactions as a first step toward the identification 
of distinct bacterial CLR ligands and characterization of their 
biological functions.
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